Epidemiology and Management of Anxiety in Patients with Bipolar Disorder

Kauer-Sant'Anna, Marcia; Kapczinski, Flavio; Vieta, Eduard
November 2009
CNS Drugs;2009, Vol. 23 Issue 11, p953
Academic Journal
Epidemiological and clinical studies have reported a high prevalence of anxiety symptoms in bipolar disorder, either in manic or depressive episodes, although these symptoms do not always meet criteria for a specific anxiety disorder. In addition to anxiety symptoms, bipolar disorder frequently presents with co-morbid axis I conditions, with anxiety disorders being the most common co-morbidity. Therefore, the objective of this article is to review clinical and epidemiological studies that have investigated the association between bipolar disorder and anxiety. Available data on the efficacy of treatments for bipolar disorder and co-morbid anxiety disorders are also reviewed. Existing guidelines do recognize that co-morbid anxiety has a negative impact on the course and outcome of bipolar disorder; however, there have been very few double-blind, controlled trials examining the treatment response of patients with bipolar disorder and co-occurring anxiety disorders. There is some positive evidence for quetiapine, olanzapine in combination with fluoxetine or lithium, and lamotrigine with lithium, and negative evidence for risperidone. Other therapies used for bipolar disorder, including several mood stabilizers, antidepressants, atypical antipsychotics and benzodiazepines, have been shown to reduce anxiety symptoms, but specific data for their effects in patients with anxiety symptoms co-morbid with bipolar disorder are not available. The co-occurrence of anxiety and bipolar disorder has implications for diagnosis, clinical outcome, treatment and prognosis. Careful screening for co-morbid anxiety symptoms and disorders is warranted when diagnosing and treating patients with bipolar disorder.


Related Articles

  • Arsenic trioxide and olanzapine co-administration: case analysis. Kaufman, Kenneth R; Chhabra, Saurabh; Levitt, Michael; Sood, Rahul // Journal of Oncology Pharmacy Practice;Sep2011, Vol. 17 Issue 3, p260 

    QTc prolongation is associated with arsenic trioxide (ATO) treatment of acute promyelocytic leukemia (APL). Olanzapine was safely co-administered with ATO to treat co-morbid psychiatric diagnoses. It is important to closely monitor for drug—drug interactions and cumulative drug adverse...

  • Sedative hypnotic use in Alberta. Kassam, Aliya; Carter, Brian; Patten, Scott B. // Canadian Journal of Psychiatry;Apr2006, Vol. 51 Issue 5, p287 

    Objective: Benzodiazepines and similar sedative-hypnotics (BDZ-SSHs) are associated with both beneficial and adverse effects. Pharmacoepidemiologic data describing the use of these medications in contemporary Canadian populations has not been readily available. Our objective was to...

  • Persistence and Remission of Psychiatric Disorders in the Quebec Older Adult Population. Préville, Michel; Boyer, Richard; Vasiliadis, Helen-Maria; Grenier, Sébastien; Streiner, David; Cairney, John; Brassard, Joèlle // Canadian Journal of Psychiatry;Aug2010, Vol. 55 Issue 8, p514 

    Objective: To document the remission and persistence of psychiatric disorders in Quebec's older adult population. Method: Data came from the Enquête sur la sante des aînés (ESA) study conducted in 2005-2008 using a representative sample (n = 2784) of community-dwelling older adults....

  • Bipolar disorder. Colin, F. // South African Journal of Psychiatry;Aug2013 Supplement, p164 

    The article provides guidelines for treating bipolar disorder (BD) published in the South African Society of Psychiatrists (SASOP) Treatment Guidelines for Psychiatric Disorders. The epidemiology, diagnosis and clinical characteristics of bipolar disorder are discussed. Phases of BD with...

  • Comorbid Anxiety in Bipolar Disorder Alters Treatment and Prognosis. El-Mallakh, Rif; Hollifield, Michael // Psychiatric Quarterly;Jun2008, Vol. 79 Issue 2, p139 

    Mood disorders in general, and bipolar disorder in particular, are unique among the psychiatric conditions in that they are associated with extraordinarily high rates of comorbidity with a multitude of psychiatric and medical conditions. Among all the potential cormobidities, co-occurring...

  • Utility of Atypical Antipsychotics in the Treatment of Resistant Unipolar Depression. DeBattista, Charles; Hawkins, Jessica // CNS Drugs;2009, Vol. 23 Issue 5, p369 

    Many patients fail to achieve an adequate response to antidepressant medication. Growing evidence suggests that atypical antipsychotics may augment antidepressant effects, resulting in a greater potential for response. Atypical antipsychotics possess pharmacological actions that are associated...

  • Aggression, agitation, and mania with olanzapine. John, Vineeth; Rapp, Michael; Pies, Ronald; John, V; Rapp, M; Pies, R // Canadian Journal of Psychiatry;Dec1998, Vol. 43 Issue 10, p1054 

    A letter to the editor is presented in response to the topic on aggression, agitation, and mania with olanzapine.

  • Tedaviye Dirençli Anksiyete Bozukluklarında Antikonvülzanların Yeri. Tükel, Raşit // Klinik Psikofarmakoloji Bulteni;Mar2009 Supplement, Vol. 19, pS84 

    Antidepressants are the first-line pharmacological treatment approach for the anxiety disorders. Other pharmacotherapy options for anxiety disorders include benzodiazepines, atypical antipsychotics, and anticonvulsants. Evidence provided by double-blind, placebo-controlled trials demonstrates...

  • Management of treatment-resistant schizophrenia with olanzapine. Thomas, Stephanie G.; Labbate, Lawrence A.; Thomas, S G; Labbate, L A // Canadian Journal of Psychiatry;Mar1998, Vol. 43 Issue 2, p195 

    A letter to the editor is presented regarding management of schizophrenia with olanzapine in a treatment-resistant schizophrenic patient.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics